Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pulmonary artery pressure as a method for assessing hydration status in an anuric hemodialysis patient - a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The impact of hemodialysis on mortality risk and cause of death in Staphylococcus aureus endocarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of large weight reductions on measured and estimated kidney function

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Dimitrios Chanouzas
  • Julie Anne G McGregor
  • Peter Nightingale
  • Alan D Salama
  • Wladimir M Szpirt
  • Neil Basu
  • Matthew David Morgan
  • Caroline J Poulton
  • Juliana Bordignon Draibe
  • Elizabeth Krarup
  • Paula Dospinescu
  • Jessica Anne Dale
  • William Franklin Pendergraft
  • Keegan Lee
  • Martin Egfjord
  • Susan L Hogan
  • Lorraine Harper
Vis graf over relationer

BACKGROUND: Intravenous pulse methylprednisolone (MP) is commonly included in the management of severe ANCA associated vasculitis (AAV) despite limited evidence of benefit. We aimed to evaluate outcomes in patients who had, or had not received MP, along with standard therapy for remission induction in severe AAV.

METHODS: We retrospectively studied 114 consecutive patients from five centres in Europe and the United States with a new diagnosis of severe AAV (creatinine > 500 μmol/L or dialysis dependency) and that received standard therapy (plasma exchange, cyclophosphamide and high-dose oral corticosteroids) for remission induction with or without pulse MP between 2000 and 2013. We evaluated survival, renal recovery, relapses, and adverse events over the first 12 months.

RESULTS: Fifty-two patients received pulse MP in addition to standard therapy compared to 62 patients that did not. There was no difference in survival, renal recovery or relapses. Treatment with MP associated with higher risk of infection during the first 3 months (hazard ratio (HR) 2.7, 95%CI [1.4-5.3], p = 0.004) and higher incidence of diabetes (HR 6.33 [1.94-20.63], p = 0.002), after adjustment for confounding factors.

CONCLUSIONS: The results of this study suggest that addition of pulse intravenous MP to standard therapy for remission induction in severe AAV may not confer clinical benefit and may be associated with more episodes of infection and higher incidence of diabetes.

OriginalsprogEngelsk
TidsskriftBMC Nephrology
Vol/bind20
Udgave nummer1
Sider (fra-til)58
ISSN1471-2369
DOI
StatusUdgivet - 18 feb. 2019

ID: 58585579